# SYL040012, Treatment for Open Angle Glaucoma

> **NCT02250612** · PHASE2 · COMPLETED · sponsor: **Sylentis, S.A.** · enrollment: 184 (actual)

## Conditions studied

- Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** 1 drop of 0.375% SYL040012 (bamosiran)
- **DRUG:** 1 drop of 0.750% SYL040012 (bamosiran)
- **DRUG:** 1 drop of 1.125% SYL040012 (bamosiran)
- **DRUG:** 1 drop of 1.5% SYL040012 (bamosiran)
- **DRUG:** 1 drop of 0.5 % timolol maleate

## Key facts

- **NCT ID:** NCT02250612
- **Lead sponsor:** Sylentis, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-08
- **Final completion:** 2016-01
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2021-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02250612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02250612, "SYL040012, Treatment for Open Angle Glaucoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02250612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*